XmAb-30819

N/A

Report date: 2026/03/19 16:59:49

Base Information

Drug NameXmAb-30819

Drug Alias NameXmAb-30819

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-Ectonucleotide pyrophosphatase/phosphodiesterase family member 3Anti-CD3

TargetsEctonucleotide pyrophosphatase/phosphodiesterase family member 3T cell surface glycoprotein CD3

Therapy Area/IndicationsCarcinoma, Renal Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesXencor Inc

China Registration ClassN/A

Develop Information

Active CompaniesXencor Inc

Inactive CompaniesN/A

Active IndicationsCarcinoma, Renal Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A